Maxim Group reaffirmed their hold rating on shares of Virpax Pharmaceuticals (NASDAQ:VRPX – Free Report) in a research note published on Wednesday, MarketBeat reports.
Virpax Pharmaceuticals Trading Up 2.4 %
Shares of NASDAQ:VRPX opened at $0.47 on Wednesday. Virpax Pharmaceuticals has a 1 year low of $0.46 and a 1 year high of $8.48. The business has a fifty day simple moving average of $0.79 and a 200 day simple moving average of $1.44.
Virpax Pharmaceuticals (NASDAQ:VRPX – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($1.75) earnings per share (EPS) for the quarter.
About Virpax Pharmaceuticals
Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Recommended Stories
- Five stocks we like better than Virpax Pharmaceuticals
- ESG Stocks, What Investors Should Know
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Top Stocks Investing in 5G Technology
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Learn Technical Analysis Skills to Master the Stock Market
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Virpax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virpax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
